Carcinoma, Non-Small-Cell Lung Clinical Trials in Burlington, Vermont

3 studies are recruiting for carcinoma, non-small-cell lung in Burlington, Vermont right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

    The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including f…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    The University of Vermont Medical Center Inc., Burlington, Vermont
    Locations
    418 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06119581 on ClinicalTrials.gov

  2. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

    The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective th…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    The University of Vermont Medical Center Inc., Burlington, Vermont
    Locations
    369 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06890598 on ClinicalTrials.gov

  3. A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

    The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is comp…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Vermont Medical Center, Burlington, Vermont
    Locations
    43 in total
    Run by
    Johnson & Johnson Enterprise Innovation Inc.

    See if you can join NCT06667908 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.